CP
ABBV icon

Cumberland Partners’s AbbVie ABBV Stock Holding History

Cumberland Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.55M Sell
25,507
-14,525
-36% -$3.22M 0.42% 41
2025
Q4 		$9.15M Sell
40,032
-4,200
-9% -$957K 0.56% 39
2025
Q3 		$10.2M Buy
44,232
+19,130
+76% +$3.9M 0.67% 32
2025
Q2 		$4.66M Buy
25,102
+1,545
+7% +$287K 0.32% 58
2025
Q1 		$4.94M Buy
23,557
+4,175
+22% +$812K 0.38% 52
2024
Q4 		$3.44M Sell
19,382
-8,615
-31% -$1.58M 0.24% 67
2024
Q3 		$5.53M Sell
27,997
-14,850
-35% -$2.77M 0.38% 54
2024
Q2 		$7.35M Buy
42,847
+14,395
+51% +$2.38M 0.53% 42
2024
Q1 		$5.18M Buy
+28,452
New +$4.9M 0.38% 55
2023
Q3 		– Sell
-20,262
Closed -$2.73M – 172
2023
Q2 		$2.73M Buy
20,262
+14,560
+255% +$2.14M 0.25% 75
2023
Q1 		$909K Sell
5,702
-30,790
-84% -$4.71M 0.09% 108
2022
Q4 		$5.9M Sell
36,492
-16,980
-32% -$2.6M 0.62% 35
2022
Q3 		$7.18M Buy
53,472
+10,085
+23% +$1.45M 0.76% 33
2022
Q2 		$6.65M Buy
43,387
+20,925
+93% +$3.2M 0.63% 41
2022
Q1 		$3.64M Buy
22,462
+14,012
+166% +$2.04M 0.28% 70
2021
Q4 		$1.14M Buy
+8,450
New +$998K 0.08% 122
2019
Q1 		– Sell
-7,000
Closed -$645K – 162
2018
Q4 		$645K Buy
7,000
+115
+2% +$10.1K 0.07% 117
2018
Q3 		$651K Sell
6,885
-7,650
-53% -$725K 0.06% 125
2018
Q2 		$1.35M Buy
+14,535
New +$1.42M 0.14% 91

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cumberland Partners's ABBV Position: Q1 2026 in Review

Cumberland Partners reduced its AbbVie (ABBV) stake by 36% in Q1 2026, selling an estimated $3.22M and leaving 25,507 shares worth $5.55M. The position accounts for 0.42% of the portfolio, ranked #41.

Cumberland Partners first reported a position in ABBV in Q2 2018 and has held it in 19 quarters since. The position peaked at $10.2M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Cumberland Partners held 25,507 shares of AbbVie worth $5.55M as of Q1 2026.
  • Cumberland Partners sold 14,525 AbbVie shares in Q1 2026, an estimated $3.22M.
  • AbbVie made up 0.42% of Cumberland Partners's portfolio in Q1 2026, its #41 holding.
  • Cumberland Partners first reported a position in AbbVie in Q2 2018 and has held it in 19 quarters since.
  • Cumberland Partners's AbbVie position peaked at $10.2M in Q3 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Cumberland Partners's 13F filing for Q1 2026, filed 14 May 2026.